Dr. Neelapu on FDA-Approved CAR T-Cell Products Spanning Lymphoma Subtypes

Sattva Neelapu, MD, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

Sattva Neelapu, MD, a professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

CAR T-cell therapy was initially approved by the FDA for patients who had relapsed/refractory large B-cell lymphomas, according to Neelapu. However, these therapies have since been investigated in early lines of therapy, as is being done in the phase 2 ZUMA-12 study (NCT03761056), as well as in other lymphoma subtypes, including mantle cell lymphoma (MCL) and indolent non-Hodgkin lymphoma (NHL).

At least 3 FDA-approved products have emerged for patients with relapsed/refractory large B-cell lymphoma in the third-line setting, Neelapu says. Additionally, brexucabtagene autoleucel (Tecartus; formerly KTE-X19) was approved by the FDA in July 2020 for use in adult patients with relapsed/refractory MCL.

Importantly, other ongoing clinical trials are examining other CAR T-cell therapies in patients with MCL or indolent NHL. Due to this, additional approvals are expected in the near future for these lymphoma subtypes, Neelapu concludes.

Related Videos
View All
Related Content